百利天恒(02615)11月7日至11月12日招股 预计11月17日上市

Core Viewpoint - The company, Baili Tianheng, is set to launch an IPO from November 7 to November 12, 2025, aiming to issue 8.6343 million shares at a price range of HKD 347.5 to HKD 389 per share, with a significant portion allocated for international investors [1] Group 1: Business Overview - The company operates as a comprehensive medical enterprise with capabilities in early research, clinical development, production, and commercialization, focusing on innovative biopharmaceuticals and generic medicines [1] - The company has developed a unique dual-specific antibody ADC, iza-bren, which is the first of its kind to enter Phase III clinical trials, and has established a strategic partnership with BMS valued at USD 8.4 billion [2] - The company has built a robust pipeline of 10 ADC candidates and has conducted approximately 70 clinical studies, including key trials in China and globally [2] Group 2: Product Portfolio - The company has accumulated expertise in the generic and traditional Chinese medicine sectors, with a product portfolio covering anesthesia, parenteral nutrition, anti-infection, and pediatrics [3] - The revenue from over 100 specifications of 31 approved drugs, including 26 generic and 5 traditional Chinese medicine products, plays a crucial role in funding the development of innovative drugs [3] Group 3: Investment and Financials - The company has secured cornerstone investment agreements with several investors, committing to purchase shares worth approximately USD 32 million or about HKD 249 million [3] - The estimated net proceeds from the global offering, based on a median price of HKD 368.25 per share, are expected to be around HKD 3.018 billion, with allocations for R&D, supply chain establishment, and operational funding [4]